青光眼患者的不良反应与安全性:关于滴眼液报告临床试验结局的共识(ASGARD)——一项德尔菲共识声明
该改良德尔菲共识邀请来自欧洲、北美、南美、中东和亚洲的临床专家参与两轮网络调查,旨在建立抗青光眼滴眼液不良反应临床试验中应采用的结局和方法的共识。第一轮71名专家对84项内容进行评分,68项(81%)达成共识;第二轮53名参与者对19项内容(含3项新增)进行评分,所调查项目中98%达成共识。最终提出一套基于共识的结局与评估方法,以期提高未来试验结果的可比性并促进荟萃分析。
要点
- 共识建议未来试验评估眼表、干涩、上皮损伤、患者报告的局部不良反应、眼周及眼睑、生活质量问卷、充血、视力、泪膜和前房炎症等结局。
- 第一轮84项中68项(81%)达成共识,第二轮所调查项目中98%达成共识。
- 该共识旨在提高抗青光眼滴眼液不良反应试验结果的可比性并促进荟萃分析。
核心结论
- 作者提出一套基于共识的结局与评估方法,用于评估抗青光眼滴眼液不良反应的临床试验,希望借此提高未来试验结果的可比性并促进该领域的荟萃分析和进展。
研究设计与样本
- 采用改良德尔菲法,邀请来自欧洲、北美、南美、中东和亚洲的临床专家参与2轮连续的网络调查,调查时间为2021年6月27日至2021年8月29日。
- 共邀请91名临床专家,其中来自23个不同国家的71名(78%)专家接受邀请并回答了第一份问卷。
- 第一轮由71名参与者对84项内容进行评分,第二轮由53名(75%)参与者对19项内容(包括3项新增内容)进行评分。
主要发现
- 第一轮84项中有68项(81%)达成共识。
- 第二轮所调查项目中98%达成共识。
- 以下8类结局被一致认为在未来试验中重要:眼表、干涩、上皮损伤、患者报告的滴眼液相关局部不良反应、眼周环境与眼睑、生活质量问卷、充血、视力、泪膜和前房炎症。
关键数值与推荐
- 项目重要性采用10分制评分(1分为不重要,10分为非常重要)。
- 未来试验中重要结局包括眼表、干涩、上皮损伤、患者报告的局部不良反应、眼周环境与眼睑、生活质量问卷、充血、视力、泪膜和前房炎症。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study is to establish consensus among experts on outcomes and methods to be used in clinical trials to assess adverse effects of anti-glaucomatous eye drops. DESIGN: Modified Delphi method. METHODS: Clinical experts from Europe, North America, South America, the Middle East, and Asia were invited to participate in 2 sequential web-based surveys administered from June 27 to August 29, 2021. A total of 91 clinical experts were invited to participate. Of these, 71 (78%) experts from 23 different countries accepted the invitation and answered the first questionnaire. The importance of items was ranked using a 10-point scale (1 as not important, 10 as very important). RESULTS: A total of 84 items were rated in round one by 71 participants. Of these, 68 (81%) reached consensus. In round 2, 19 items, including 3 additional items, were rated by 53 (75%) participants. Consensus was reached in 98% of investigated items. Eight outcomes were agreed as important to assess when conducting future trials: ocular surface, dryness, epithelial damage, local adverse effects related to eye drops as reported by patients, periocular surroundings and eyelids, quality of life questionnaires, hyperemia, visual acuity, tear film, and anterior chamber inflammation. CONCLUSION: We propose a consensus-based series of outcomes and assessment methods to be used in clinical trials assessing adverse effects of antiglaucomatous eye drops. This, we hope, will improve the comparability of results from future trials and thus facilitate meta-analyses and progress in this field.
引用
- Thein AS, Hedengran A, Azuara-Blanco A, et al. Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement. Am J Ophthalmol. 2022. PMID: 35594917. doi:10.1016/j.ajo.2022.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。